Thymidylate Synthase Polymorphism and Colorectal Cancer Survival
Author Information
Author(s): Ulrich C M, Potter J D
Primary Institution: Cancer Prevention Research Program, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Hypothesis
Do thymidylate synthase polymorphisms affect the survival of colorectal cancer patients treated with 5-fluorouracil?
Conclusion
The interpretation of the study results regarding the impact of thymidylate synthase polymorphisms on survival benefits from chemotherapy is misleading.
Supporting Evidence
- Patients with the 3R/3R polymorphism showed no significant long-term survival benefit from chemotherapy.
- Those with the 2R/2R or 2R/3R genotype showed significant gains in survival.
- The authors did not perform a statistical test to compare survival benefits between genotypes.
Takeaway
The study looked at how different gene types affect cancer treatment success, but the results were not presented clearly, leading to confusion about their meaning.
Methodology
The study analyzed survival rates among colorectal cancer patients with different thymidylate synthase genotypes receiving chemotherapy.
Potential Biases
The presentation and interpretation of results may mislead readers regarding the significance of the findings.
Limitations
The study did not perform statistical tests to compare survival benefits between different genotypes.
Participant Demographics
Colorectal cancer patients treated with 5-fluorouracil.
Statistical Information
P-Value
0.005
Confidence Interval
0.30–1.25, 0.52–0.82
Statistical Significance
p=0.005
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website